TABLE 1.
Baseline and transplant characteristicsa
| Baseline and transplant characteristics | All cases (n = 53) |
|---|---|
| Median (range) age (yr) | 60 (46-65) |
| Female patients | 20 (37.7) |
| Liver transplant recipients | 4 (7.5) |
| Kidney transplant recipients | 4 (7.5) |
| Combined liver-kidney transplant recipient | 1 (1.9) |
| Lung transplant recipients | 44 (83) |
| Respiratory disease | |
| Pulmonary fibrosis (IPF, connective tissue disease, hypersensibility pneumonitis…) | 24 (54.5) |
| COPD | 9 (20.5) |
| Pulmonary hypertension | 6 (13.6) |
| Cystic fibrosis | 4 (9.1) |
| Previous lung transplant | 2 (4.5) |
| Bilateral lung transplant | 30 (68.2) |
| Bronchial stenosis | 10 (22.7) |
| Bronchial dilatations | 5 (11.4) |
| Bronchial stent | 4 (9.1) |
| CLAD | 10 (22.7) |
| BOS | 6 (60) |
| RAS | 2 (20) |
| Mixed or undefined CLAD | 2 (20) |
| Emergency transplant procedure | 6 (11.3) |
| ECMO pretransplant | 1 (1.9) |
| ECMO in early post transplant | 2 (3.8) |
| Use of ECC | 14 (26.4) |
| Previous FI | 11 (20.8) |
| Aspergillus spp. | 8 (72.7) |
| Immunosuppression with tacrolimus, mycophenolate mofetil and corticosteroids | 50 (94.3) |
| Antifungal prophylaxis | 45 (84.9) |
| Nebulized amphotericin B | 43 (95.6) |
| Micafungin | 1 (2.2) |
| Under antifungal treatment due to FI before transplantation | 1 (2.2) |
a
Data are expressed as numbers (%) unless otherwise indicated. BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; COPD, chronic obstructive pulmonary disease; ECC, extracorporeal circulation; ECMO, extracorporeal membrane oxygenation; FI, fungal infection; ICU, intensive care unit; IQR, interquartile range; IPF, idiopathic pulmonary fibrosis; RAS, restrictive allograft syndrome.